, explains the background of the study, “Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer,” which was published in the 

. Packiam is a clinical assistant professor of Urology, Department of Urology, University of Iowa Hospitals and Clinics.

Bladder Cancer

Vignesh Packiam, MD, explains how innovation driven by the BCG shortage led to a potential promising new regimen of sequential intravesical gemcitabine and docetaxel for patients with BCG-naïve non–muscle-invasive bladder cancer. 

Dr. Packiam on background of study of sequential intravesical chemo in BCG-naïve NMIBC